Hybio Pharmaceutical Co., Ltd.

Company Overview

Hybio Pharmaceutical is a dedicated and the first listed peptide producer in China (established in 2003 and went public in 2011). We offer a full range of peptides, such as Liraglutide, Semaglutide, Ganirelix, Leuprorelin Acetate, Desmopressin, Glatiramer, Degarelix, Terlipressin etc. Hybio API manufacturing plant is US FDA approved (2015&2018), EU AEMPS approved (2015) and KFDA approved (2018) and the new API site has an expected capacity of 1000kg/year. Besides, we have peptide injections, such as Atosiban injection (approved in Spain and Germany), Terlipressin for injection, Eptifibatide injection etc, where the plant is EU GMP approved.